Jun 08, 2020
Akcea announces approval for reimbursement of TEGSEDI® (inotersen) in Italy for treatment of hereditary transthyretin amyloidosis with polyneuropathy
May 14, 2020
Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Spain for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
Mar 05, 2020
Amyloidosis Patient Registry Hits 300 Participants and is Now Available to Entire Community
Oct 03, 2019
Excelera Network® and Pfizer Partner for Distribution of World's First Treatment for Transthyretin Amyloid Cardiomyopathy
Jul 23, 2019
Alnylam Launches ONPATTRO® (patisiran) for the Treatment of Polyneuropathy in hATTR Amyloidosis, the First-Ever RNAi Therapeutic Approved in Canada
May 01, 2019
Positive clinical data at AAN 2019 reinforces Ionis' commitment to delivering life-changing medicines to patients with neurological diseases
Nov 13, 2018
Global $6.7 Billion Amyloidosis Treatment Market to 2023 - Key Players are Alnylam, Ionis, Pfizer, Johnson & Johnson and Takeda
Aug 02, 2018
Akcea Therapeutics and PTC Therapeutics Collaborate to Commercialize Two Rare Disease Drugs in Latin America
May 03, 2018
Eidos Therapeutics Initiates Phase 2 Clinical Trial for AG10 Targeting Transthyretin Amyloidosis Cardiomyopathy
Apr 17, 2018
Presentations at the 2018 American Academy of Neurology Highlight the Broad Potential of Antisense Drugs for Neurological Diseases
Apr 05, 2018
Eidos Therapeutics completes $64M Series B financing
Mar 26, 2018
Ionis and Akcea Present New Data from ATTR Amyloidosis Program at 16th International Symposium on Amyloidosis
Mar 20, 2018
Eidos Therapeutics to Host Symposium on TTR Stabilization at the 16th International Symposium on Amyloidosis